The use of amphiphilic copolymer in the solid dispersion formulation of nimodipine to inhibit drug crystallization in the release media: Combining nano-drug delivery system with solid preparations.

Administration, Oral Animals Caco-2 Cells Crystallization Drug Compounding Drug Delivery Systems Drug Liberation Endocytosis Gastrointestinal Tract / drug effects Humans Mice Micelles Nanoparticles / chemistry Nimodipine / administration & dosage Polyethylene Glycols / chemistry Polyvinyls / chemistry Povidone / analogs & derivatives Solutions Surface-Active Agents / chemistry
Amphiphilic copolymer Crystallization inhibition Drug release Nano-drug delivery system Nimodipine solid dispersions

Journal

Materials science & engineering. C, Materials for biological applications
ISSN: 1873-0191
Titre abrégé: Mater Sci Eng C Mater Biol Appl
Pays: Netherlands
ID NLM: 101484109

Informations de publication

Date de publication:
Jun 2020
Historique:
received: 15 01 2020
revised: 10 03 2020
accepted: 11 03 2020
entrez: 14 4 2020
pubmed: 14 4 2020
medline: 8 1 2021
Statut: ppublish

Résumé

Solid dispersion is a widely used method to improve the dissolution and oral bioavailability of water-insoluble drugs. However, due to the strong hydrophobicity, the drug crystallization in the release media after drug dissolution and the resulted decreased drug absorption retards the use of solid dispersions. It is widely known that the amphiphilic copolymer can encapsulate the hydrophobic compounds and help form stable nano-dispersions in water. Inspired by this, we tried to formulate the solid dispersion of nimodipine by using amphipathic copolymer as one of the carriers. Concerning the solid dispersions, there are many important points involved in these formulations, such as the miscibility between the drug and the carriers, the storage stability of solid dispersions, the dissolution enhancement and so on. In this study, a systemic method is proposed. In details, the supersaturation test and the glass transition temperature (T

Identifiants

DOI: 10.1016/j.msec.2020.110836 PMID: 32279765
pubmed: 32279765
pii: S0928-4931(20)30206-X
doi: 10.1016/j.msec.2020.110836
pii:
doi:

Substances chimiques

Micelles 0
Polyvinyls 0
Solutions 0
Surface-Active Agents 0
polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer 0
vinylacetate-vinylpyrrolidone copolymer 0
Polyethylene Glycols 3WJQ0SDW1A
Nimodipine 57WA9QZ5WH
Povidone FZ989GH94E

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

110836

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare no conflict of interest.

Auteurs

Min-Yan Wei (MY)

The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong 510700, China; The State Key Laboratory of Respiratory Disease, Guangzhou Medical University, Guangzhou, Guangdong, China; The Key Laboratory of Molecular Target & Clinical Pharmacology, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, China.

Xue-Ping Lei (XP)

The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong 510700, China; The State Key Laboratory of Respiratory Disease, Guangzhou Medical University, Guangzhou, Guangdong, China; The Key Laboratory of Molecular Target & Clinical Pharmacology, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, China.

Jing-Jing Fu (JJ)

Jiangsu Provincial Xuzhou Pharmaceutical Vocational College, Xuzhou 221116, China.

Ming-Yue Chen (MY)

The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong 510700, China; The State Key Laboratory of Respiratory Disease, Guangzhou Medical University, Guangzhou, Guangdong, China; The Key Laboratory of Molecular Target & Clinical Pharmacology, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, China.

Jie-Xia Li (JX)

The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong 510700, China; The State Key Laboratory of Respiratory Disease, Guangzhou Medical University, Guangzhou, Guangdong, China; The Key Laboratory of Molecular Target & Clinical Pharmacology, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, China.

Xi-Yong Yu (XY)

The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong 510700, China; The State Key Laboratory of Respiratory Disease, Guangzhou Medical University, Guangzhou, Guangdong, China; The Key Laboratory of Molecular Target & Clinical Pharmacology, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, China.

Yin-Lei Lin (YL)

School of Materials Science and Energy Engineering, Foshan University, Foshan 528000, China.

Jing-Ping Liu (JP)

Department of Clinical Laboratory, The Third Affiliated Hospital, Southern Medical University, Guangzhou, China.

Ling-Ran Du (LR)

The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong 510700, China; The State Key Laboratory of Respiratory Disease, Guangzhou Medical University, Guangzhou, Guangdong, China; The Key Laboratory of Molecular Target & Clinical Pharmacology, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, China.

Xin Li (X)

The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong 510700, China; The State Key Laboratory of Respiratory Disease, Guangzhou Medical University, Guangzhou, Guangdong, China; The Key Laboratory of Molecular Target & Clinical Pharmacology, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, China.

Yu Zhang (Y)

The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong 510700, China; The State Key Laboratory of Respiratory Disease, Guangzhou Medical University, Guangzhou, Guangdong, China; The Key Laboratory of Molecular Target & Clinical Pharmacology, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, China.

Ying-Ling Miao (YL)

The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong 510700, China; The State Key Laboratory of Respiratory Disease, Guangzhou Medical University, Guangzhou, Guangdong, China; The Key Laboratory of Molecular Target & Clinical Pharmacology, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, China.

Yu-Gang Huang (YG)

The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong 510700, China; The State Key Laboratory of Respiratory Disease, Guangzhou Medical University, Guangzhou, Guangdong, China; The Key Laboratory of Molecular Target & Clinical Pharmacology, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, China. Electronic address: hyug@gzhmu.edu.cn.

Lu Liang (L)

The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong 510700, China; The State Key Laboratory of Respiratory Disease, Guangzhou Medical University, Guangzhou, Guangdong, China; The Key Laboratory of Molecular Target & Clinical Pharmacology, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, China. Electronic address: lliangaa@gzhumu.edu.cn.

Ji-Jun Fu (JJ)

The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong 510700, China; The State Key Laboratory of Respiratory Disease, Guangzhou Medical University, Guangzhou, Guangdong, China; The Key Laboratory of Molecular Target & Clinical Pharmacology, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, China. Electronic address: fujj@gzhmu.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Voies d'administration de substances chimiques et des médicaments › Administration par voie orale › The use of amphiphilic copolymer in the solid...
questionsmedicales.fr › Eucaryotes › Animaux › The use of amphiphilic copolymer in the solid...
questionsmedicales.fr › Cellules › Cellules épithéliales › Cellules Caco-2 › The use of amphiphilic copolymer in the solid...
questionsmedicales.fr › Phénomènes chimiques › Cristallisation › The use of amphiphilic copolymer in the solid...
questionsmedicales.fr › Techniques d'investigation › Préparation de médicament › The use of amphiphilic copolymer in the solid...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Systèmes de délivrance de médicaments › The use of amphiphilic copolymer in the solid...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Pharmacocinétique › Libération de médicament › The use of amphiphilic copolymer in the solid...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Endocytose › The use of amphiphilic copolymer in the solid...
questionsmedicales.fr › Système digestif › Tube digestif › The use of amphiphilic copolymer in the solid...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › The use of amphiphilic copolymer in the solid...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › The use of amphiphilic copolymer in the solid...
questionsmedicales.fr › Préparations pharmaceutiques › Micelles › The use of amphiphilic copolymer in the solid...
questionsmedicales.fr › Technologie, industrie et agriculture › Produits manufacturés › Nanostructures › Nanoparticules › The use of amphiphilic copolymer in the solid...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyridines › Acides nicotiniques › Nimodipine › The use of amphiphilic copolymer in the solid...
questionsmedicales.fr › Technologie, industrie et agriculture › Produits manufacturés › Matériaux biomédicaux et dentaires › Polymères › Polyéthylène glycols › The use of amphiphilic copolymer in the solid...
questionsmedicales.fr › Technologie, industrie et agriculture › Produits manufacturés › Matériaux biomédicaux et dentaires › Polymères › Matières plastiques › Polyvinyles › The use of amphiphilic copolymer in the solid...
questionsmedicales.fr › Technologie, industrie et agriculture › Produits manufacturés › Matériaux biomédicaux et dentaires › Polymères › Matières plastiques › Polyvinyles › Povidone › The use of amphiphilic copolymer in the solid...
questionsmedicales.fr › Préparations pharmaceutiques › Solutions › The use of amphiphilic copolymer in the solid...
questionsmedicales.fr › Actions chimiques et utilisations › Utilisations spécialisées de produits chimiques › Tensioactifs › The use of amphiphilic copolymer in the solid...